58 results
S-3ASR
EX-5.1
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
(without making enquiry or investigation) that:
all signatures, stamps and seals on all documents are genuine. All original documents are complete … under the laws of the State of New York, and we have made no investigation of such meaning or import. Therefore, our review of the Relevant
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
in the U.S. filed with the FDA or the corresponding application for the investigation of pharmaceutical or biologic products in any other country or group … , as applicable, agree not to consummate the transactions contemplated hereunder, withdraw any filing, or authorize the extension of any investigation
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false … medicinal product must agree to a Pediatric Investigation Plan (“PIP”), with the EMA’s Pediatric Committee (“PDCO”) during drug development
8-K
EX-1.1
AUTL
Autolus Therapeutics plc
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
(collectively, the “Applicable Laws”); (ii) have not received any notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, audit … , action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action or communication threatened; (iii) possess all material
8-K
EX-5.1
AUTL
Autolus Therapeutics plc
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
or investigation) that:
all signatures, stamps and seals on all documents are genuine. All original documents are complete, authentic and up-to-date, and all … or able to assess the true meaning or import of the terms of the Agreements under the laws of the State of New York, and we have made no investigation
8-K
EX-10.1
eza0angm jybd
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
EX-5.1
043hw ash11ax
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
EX-4.7
b1mj9zty5
7 Feb 24
Automatic shelf registration
10:00pm
S-8
EX-5.1
xekdyzbajsde5wtlkh
3 Nov 23
Registration of securities for employees
4:02pm
S-8
EX-5.1
cp89paf9us3i4eahf
7 Aug 23
Registration of securities for employees
4:57pm
6-K
EX-5.1
gg2e3
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
6-K
EX-1.1
mj3wvp
9 Dec 22
Autolus Announces Pricing of Public Offering
5:43pm
6-K
EX-1
wxkxblnne063d8c
1 Jul 22
Current report (foreign)
5:15pm
F-3
EX-5.1
ztuaqpl2y 2f7pc
3 May 22
Shelf registration (foreign)
7:25pm
F-3
EX-5.1
k28xd3
14 Apr 22
Shelf registration (foreign)
9:30pm
F-6EF
EX-99
rkdrn06f28x74 c68a
9 Nov 21
Automatic registration for ADRs (foreign)
4:02pm
6-K
EX-99.1
buo31et
8 Nov 21
Securities Purchase Agreement
5:28pm
F-3
EX-5.1
p3uq usqbt
6 Aug 21
Shelf registration (foreign)
2:30pm